Clovis Oncology's (CLVS) Rubraca Significantly Improves PFS versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation

Clovis Oncology’s Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation

Data from the randomized, Phase 3 ARIEL4 study to be presented today at the Society of Gynecologic Oncology Virtual Annual Meeting on Womens Cancer The ARIEL4 study met its primary endpoint, showing a statistically significant improvement in investigator-assessed progression-free survival (PFS) for Rubraca versus chemotherapy The safety of Rubraca observed in the ARIEL4 study was highly consistent with both the U.S. and EU product labels

 

BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced that the first presentation of data... More